The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
How many tests are they processing at this facility??
So at last we seem to be getting some confirmation that when our board talk of "validated" tests, they are referring to laboratory validation and not the large scale randomised trial validation that doctors require before adopting a test routinely.
I notice too that recent pronouncements about the companies targets for 2024 make no mention of participation in the Transform trial (funded by Prostate Cancer UK and the Government). The probability that OBD will need to fund and manage such trials is a major risk of delay to mass commercial sales and would require further placings to finance. Burrows said participation in Transform was crucial so why isn't it in the company's targets for this year?
Ok not sales but positive rns . Atb
Well there is absolutely ZERO feedback from the AGM which signifies a flat out WIN for Burrowes and his cronies.
£12 k buy some one is keen?
What an incompetent BOD Oxford has run by the biggest olonker on aim, Burrows !!!
£400k a year
And can’t justify it
Hey I’m just the milkman’s son. Granted my father was the fastest in the west . Have expressed my opinion many times now. As the great mf doom once rapped ‘ sometimes you rhyme quick, sometimes you rhyme slow or vice versa .’
Ah. The return of the milkman's son.
If you would have gone to lend your support to the board you would know and wouldn't need to ask. Ignorance, borne of a lack of knowledge seems to follow you through life.
Anyone of you moaners actually attend then?
It would be classic if someone did ask about his daughter being on the payroll though, just to see look on his face. And actually it would be quite reasonable to ask whether that role was advertised to external candidates as part of a proper recruitment process, whether £55k part time represents good value for shareholder money and the thinking behind her receiving a 25% year on year pay increase.
Does anyone have any positive feelings towards our survival here? I do hear all what's gone on, and how we feel about the board, how this has played out, the dales being really not up to scratch. The heavy salary intake and the marketing team not fit to sell apples.
But surely we have something we think can turn it around that your still hoping on?
With respect Dibs that's a bit like guaranteeing the sun will set tonight.
The only people with sufficient clout to.make their life difficullt are the II's and even though they must be having doubts about him now, they will have had a major say in hos appointment.
Sadly Burrow's and his cronies don't give a t### about PI's as is evident from the lack of response to the many issues I and others have raised with investor relations. If folks like Aga do go to the AGM I hope they get a hearing but it will probably be stage managed to avoid disturbing the pigs feeding at the trough.
I’ll guarantee after all the noise on here Burrowes will get a relatively easy ride tomorrow.
He and his cronies will get voted back in and it’ll be back to BAU.
For the record, I am invested here and also BOIL and underwater in both. I wouldn’t have the first clue how to short something and wouldn’t want to, as don’t agree with it.
I have reported that poster for defamation. I hope LSE remove it.
Wow. How sad that this ‘poster’ who started abusing me, this morning because I called him out for his blatant, mindless ramping, has stalked me to here.
Check its history people. And two of you recommended it. 🙄
The BoD has a tendency to spin news and cannot be trusted to be transparent with shareholders. The announcement that sales were growing exponentially on a month by month basis is impossible to reconcile with the reality.The BUPA deal was met with a statement that all BUPA patients being considered for immunotherapy would undergo CIRT test has now morphed into a series of seminars aimed at convincing BUPA consultants that they should do so. Validated tests are lab validated only which is a million miles from the standards required for tests that potentially have life changing consequences for those acting on the results. I'd gladly see Burrows and his hangers-on replaced by a completely new board and senior management team. The only thing I believe about them is they virtually all have second jobs. Their salaries ain't bad for part-timers.
Oxford BioDynamics Plc (OBD.L) has experienced significant price movements over the past year, with its price ranging from 9.00 GBp to 52.00 GBp. Such volatility suggests the stock has been subject to various market forces and potentially internal company developments. The company's market cap is 19.583M, and it has recently closed at 9.68 GBp, indicating a 1.47% increase. Despite the recent gains, the stock's performance has been challenging, with a year-to-date decline of -64.15% and a five-year decline of -93.66%.
This deep analysis considers the company's operational field in biotechnology and recent strategic agreements, such as with Bupa for the EpiSwitch® CiRT for cancer patients and the U.S. launch of its EpiSwitch® Prostate Screening Blood Test. These initiatives reflect Oxford BioDynamics' efforts to expand its market presence and revenue streams. However, the financials show a company in a delicate phase, with negative EPS (TTM) of -0.07 and no PE Ratio, reflecting the current unprofitability.
Considering these factors, the potential future performance of Oxford BioDynamics' stock could hinge on the successful commercialization of its biotechnological innovations and the broader market's reception of these advances. If the company can leverage its strategic initiatives to generate sustainable revenue growth, there could be potential for stock price recovery. However, the current financial health and the stock's significant historical decline suggest cautious optimism. Investors might look for signs of sustained financial improvement and market acceptance of its products before a strong positive momentum can be established.
---
Don’t believe a word this Pompal🤡 telling you guys.
This crook pumped BOIL and then he shorted it out.
He’s a cunning individual who has history of making money of poor investors.
Good luck to LH here 👍 ATB
I have a simple question. I have BUPA. How do I get a Pse/Psa test done?
Another question . What the hell do they do all day long ? And what other jobs do they have?
404x, your second paragraph pretty much tells the story. This shiester pays his daughter £55k to be a part time ‘social media specialist’. To do what, exactly? Small fry in the grand scheme but relevant, nonetheless. IMV, this is nothing more than a lifestyle company for quite a few people.
When do they expect to at least break even, so that the company no longer has to rely on placings to stay afloat?
This is key as over the years they've made over £40m by selling shares but very little commercially. For all their hype revenue remains tiny but we're not talking about a startup anymore, it's been listed for coming for 8 years now. If there's no end in sight for these placings and shareholders know another round of dilution is perpetually around the corner, it will always damage the investment case.
I would endorse what DugWalker suggested ref AGM questions.
..this time it's a threat to the much vaunted product pipeline that 3rd parties are queuing up to licence.
https://www.proactiveinvestors.co.uk/companies/news/1043762/angle-shares-up-as-nhs-move-reveals-potential-of-liquid-biopsy-systems-1043762.html
The article contains an interesting remark about regulatory approval in the US.
WRT the AGM, It'd be worth asking what regulatory approvals are required for CIRT and PSE before we get unfettered access to the market and to what extent has this impacted commercialisation.
If they suggest it hasn't then I'd ask why they have charged Arivo and Mathis with getting tests included in medical guidance notes.
Fellow Investors.
Any of you thinking of going to the AGM.
I think some questions need answered.
I am hoping to go and would be happy if you have any questions that you would like me to put to the BODs then please post them here as soon as you can.
GLA LTHs.
Isn't it it crazy that I'm a world were this is needed, and thus product that has amazing benefits, has zero people knowing about it high and wide, go figure!